H.C. Wainwright analyst Ram Selvaraju has reiterated their bullish stance on ABEO stock, giving a Buy rating yesterday.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Ram Selvaraju has given his Buy rating due to a combination of factors including the promising outlook for Abeona Therapeutics’ product, ZEVASKYN, despite a slower than expected rollout. The product, approved for treating recessive dystrophic epidermolysis bullosa (RDEB), faced initial setbacks due to a false positive result in a sterility assay, but the company has since optimized the process and resumed operations, expecting commercial treatments to commence shortly.
Additionally, the market access and reimbursement landscape for ZEVASKYN appears favorable, with positive coverage established by major insurers and a permanent HCPCS J-code effective from January 2026. Although the company missed revenue expectations for 3Q25 due to no patient treatments, the financial outlook remains positive with anticipated revenue growth and a strong cash position expected to support operations for over two years.
According to TipRanks, Selvaraju is a 5-star analyst with an average return of 23.3% and a 51.40% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Bioxcel Therapeutics, Emergent Biosolutions, and Genmab.
In another report released yesterday, Stifel Nicolaus also maintained a Buy rating on the stock with a $19.00 price target.